Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 2/6 |
Rewards
Risk Analysis
Viatris Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.76 |
52 Week High | US$13.62 |
52 Week Low | US$8.74 |
Beta | 0.94 |
11 Month Change | 14.06% |
3 Month Change | 1.64% |
1 Year Change | 13.84% |
33 Year Change | -17.70% |
5 Year Change | -42.13% |
Change since IPO | 1,817.91% |
Recent News & Updates
Recent updates
Viatris: Revenues, Debt, Valuation And Strategy Under The Microscope
Jun 13Viatris: Skeptics Proven Right Once Again
May 30Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.
Apr 24Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential
Apr 08Viatris Stock Is Still Worth Buying
Mar 30Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued
Mar 02From Euphoria To Reality: Viatris' Tale Of Market Whirlwind
Jan 12Viatris stock rises amid potential plans for €3B sale of European OTC assets
Oct 11Take These Broken Wings And Learn To Fly Again Viatris
Sep 25Viatris: 5% Dividend Yield Is A Threat For Investors
Sep 06Viatris: Products, Profitability And Pipeline - The Keys To Success
Aug 20Viatris declares $0.12 dividend
Aug 08Viatris: A Spinoff To Own
Aug 02Viatris extends decline to reach 52-week low
Jul 22Viatris: Guidance Likely To Be Cut With Q2 Results
Jul 15Shareholder Returns
VTRS | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -0.08% | 0.004% | -2.4% |
1Y | 13.8% | 18.8% | 17.5% |
Return vs Industry: VTRS underperformed the US Pharmaceuticals industry which returned 18.8% over the past year.
Return vs Market: VTRS underperformed the US Market which returned 17.5% over the past year.
Price Volatility
VTRS volatility | |
---|---|
VTRS Average Weekly Movement | 3.6% |
Pharmaceuticals Industry Average Movement | 9.9% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VTRS has not had significant price volatility in the past 3 months.
Volatility Over Time: VTRS's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1961 | 33,000 | Scott Smith | www.viatris.com |
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).
Viatris Inc. Fundamentals Summary
VTRS fundamental statistics | |
---|---|
Market cap | US$13.93b |
Earnings (TTM) | -US$56.10m |
Revenue (TTM) | US$15.36b |
0.9x
P/S Ratio-249.6x
P/E RatioIs VTRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VTRS income statement (TTM) | |
---|---|
Revenue | US$15.36b |
Cost of Revenue | US$8.68b |
Gross Profit | US$6.68b |
Other Expenses | US$6.73b |
Earnings | -US$56.10m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
Earnings per share (EPS) | -0.047 |
Gross Margin | 43.47% |
Net Profit Margin | -0.37% |
Debt/Equity Ratio | 89.7% |
How did VTRS perform over the long term?
See historical performance and comparison